Business

EU fines drug firms over delay

AMSTERDAM — The European Commission has fined pharmaceuticals giants Johnson & Johnson and Novartis a combined $22 million for colluding to delay the entrance of a cheap generic form of a pain killer to the Dutch market.

In a statement, the commission’s antitrust chief, Joaquin Almunia, said the two companies ‘‘shockingly deprived patients in the Netherlands, including people suffering from cancer, from access to a cheaper version of this medicine.’’

Advertisement

The commission found that after Johnson & Johnson’s patent on a patch containing the drug Fentanyl expired in 2005, it paid Novartis to delay launching a generic version.

The delay lasted 17 months, and was more profitable for both companies than competing honestly would have been.

Get Talking Points in your inbox:
An afternoon recap of the day’s most important business news, delivered weekdays.
Thank you for signing up! Sign up for more newsletters here

J&J’s fine was $14.7 million, and Novartis’s was $7.6 million.

Associated Press

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com